Conclusions: In this randomly selected and nationally representative sample of Medicare beneficiaries and relative to matched control patients, individuals with untreated OSA demonstrated increased HCU and costs across all points of service.

Click thumbnail to view PDF →

EnsoData, the leader in Al/ML for sleep, combines our technology with best-in-class care service partners to help payers and at-risk providers dramatically improve sleep apnea treatment success.

Did you know?

Sleep apnea is prevalent in 3 of 4 people with healthcare’s most common and expensive conditions. Untreated sleep apnea diminishes the impact of ANY intervention to improve outcomes for this population.

Sleep Apnea Prevalence in Common Comorbidities
  1. Johnson KG and Johnson DC. J Clin Sleep Med 2010
  2. Einhorn D et al Endocr Pract 2007
  3. O’Keefe T and Patterson EJ. Obes Surg 2004
  4. Bitter T et al. Dtsch Aztebl Int. 2009
  5. Oldenburg O et al. Eur J Heart Fail 2007
  6. Logan AG et al. Journal of Hypertension 2001